Nearly three-fourths of life sciences organizations in a survey have invested in digital pathology to advance drug research and development, but more than half (53%) still center their operations around legacy software systems, primarily for basic image viewing, according to research commissioned by digital pathology software firm Proscia.
Its 2023 Life Sciences Digital Pathology Adoption Survey asked 40 senior executives from pharmaceutical companies and contract research organizations (CROs) about their use of digital pathology, the benefits it has delivered, and its future impacts.
Among specific findings of the survey, Proscia said, executives see digital pathology as a solution to R&D’s biggest challenges, including the expense and amount of time it takes to introduce a new drug to the market.
Artificial intelligence (AI) is already used to enable drug discovery and development, with 82% of respondents that use digital pathology saying they have begun to implement AI, the survey found.
Furthermore, digital pathology is opening a new data opportunity, with 55% of respondents indicating that creating data assets is a key driver of their digital pathology investment; pathology data informs every drug brought to market.